CXCL10 and CCL5 are chemokines that induce antitumor immunity in SCLC and other cancer types in response to type I IFNs (Morel et al., 2021; Sen et al., 2019b; Takahashi et al., 2021; Zheng et al., 2020). Here, CCL5 is linked to cancer.